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THE RESPONSE OF HeLa CELLS
TO BRIEF TREATMENT WITH
SELECTED PROXIMATE PRE- AND
NON-CARCINOGENIC AGENTS. D.
GRANT and P. GRASSO, British Industrial
Biological Research Association (BIBRA),
Carshalton, Surrey.
There is much evidence to suggest that a
wide range of cytotoxic chemicals, including
carcinogens, is able to inhibit cell prolifera-
tion. We have investigated this phenomenon
more closely in vitro by pulse-exposing HeLa
cells to a variety of cytotoxic agents, with
the eventual aim ofdeveloping an inexpensive
screening test for carcinogenic activity.
Results indicate that cell proliferation was
markedly inhibited for up to 3 days after
brief treatment with a number of proximate
carcinogens, or precareinogens given in the
presence of a rat liver homogenate. Brief
treatment with a range of non-carcinogenic
cytotoxic agents revealed a proportion which
arrested proliferation for up to 3 days after
treatment. However, further experiments
have shown that all pre- and proximate
carcinogens so far tested cause nuclear
enlargement. This was not seen when other
cytotoxic agents were tested. Thus in our
system brief exposure to a chemical which
results in arrest of cell proliferation and
nuclear enlargement may be indicative of
carcinogenic activity.
THE PARS INTERMEDIA AND RENAL
CARCINOGENESIS IN THE MALE
HAMSTER, P. G. SALUJA, A. THODY and
J. M. HAMILTON, Department of Experimental
Pathology and Cancer Research, School ofj
Medicine, Leeds.
Male hamsters 2-3 months of age were
treated for 9 months by thrice weekly injec-
tionofdiethylstilboestrol (DES). Allanimals
developed kidney tumours and histopatho-
logical examination showed that the inter-
mediate lobes of the pituitary were hyper-
plastic and neoplastic. The content of the
melanocyte-stimulating hormone (MSH) in
the pituitary glands of 17 controls and 12
DES-treated animals was measured by
bioassay and radioimmunoassay. When com-
pared with control pituitaries, the concentra-
tion of immunoreactive ax MSH in treated
animalswassignificantly elevated (P < 0 005)
with significant positive correlation between
pituitary weight and total of MSH content.
The levels of bioactive MSH were also
elevated. Serum levels of immunoreactive
a MSH were consistently higher in treated
animals. The possibility exists that the
induction of kidney tumours in the male
hamster by oestrogens is mediated via the
pituitary gland and that MSH may be of
importance in carcinogenesis.
CHRONIC LESIONS IN RATS
TREATED WITH CRUDE EXTRACTS
OF FUSARIUM POAE AND F.
SPOROTRICHIOIDES. THE ROLE
OF MOULDY FOOD IN THE INCI-
DENCE OF OESOPHAGEAL, MAM-
MARY AND CERTAIN OTHER
ABNORMALITIES AND TUMOURS
IN LIVESTOCK AND MAN, R.
SCHOENTAL, A. Z. JOFFE and B. YAGEN, Royal
Veterinary College, London and The Hebrew
University, Jerusalem.
In continuation of the investigation in
which rats were treated with extracts of
Fusaria cultures by various routes (Schoental
and Joffe, 1974, J. Pathol., 112, 37), chronic
lesions were found in a variety of organs,
including the digestive tract, brain and the
sex organs. These lesions appear to be
caused by the known toxic and oestrogenic
secondary metabolites produced by the
Fusaria. Certain abnormalities and tumours
in livestock and man may be related to the
consumption of mouldy food contaminated
by such biologically active fungal metabolites.
THE MISCODING PROPERTIES OF
04-METHYLTHYMINE IN TEM-
PLATES FOR DNA POLYMERASE.
P. J. ABBOTT and R. SAFFHILL, Paterson
Laboratories, Christie Hospital and Holt
Radium Institute, Manchester.
The alternating copolymer polyd(AT) has
been methylated with either N-methyl-N-
nitrosourea (MNU) or dimethyl sulphate
(DMS) and the levels of the various methyla-
tion products determined. Reaction with
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MNU resulted in the formation of phospho-
triesters and of 04-methylthymine, neither of
which were detected after reaction with
DMS. These methylated polymers were used
as templates for E. coli DNA polymerase I in
vitro. The incorporation of complementary
(A and T) and non-complementary (C and
G) bases into acid insoluble material was
measured using radioactive nucleoside tri-
phosphates. With the DMS-methylated
polymer, no wrong base incorporation (C orG)
was detectable, but with the MNU-methyl-
ated polymer incorporation of guanine was
observed. The amount of guanine incor-
porated correlated with the level of 04-
methylthymine in the template. The results
indicate that 04-methylthymine is capable of
gross mis-coding, while the products of
DMS methylation (1, 3- and 7-methylade-
nines) and possibly also phosphotriesters, do
not lead to mis-coding.
SCANNING ELECTRON MICRO-
SCOPY (SEM) OF THE MOUSE
CERVIX FOLLOWING THE APPLI-
CATION OF 3-4 BENZOPYRENE.
A. E. WILLIAMS, J. BEATTIE, J. M. ALLEN,
J. F. MURPHY and J. A. JORDAN, Teaching
and Research Centre, Western General Hospital,
Edinburgh and Department of Obstetrics and
Gynaecology, University of Birmingham.
Squamous, columnar and metaplastic epi-
thelia ofthe human cervix have characteristic
SEM features which differ from those of
neoplastic tissue. Cancer of the human
cervix is usually preceeded by pre-malignant
stages during which increasing abnormality
of the epithelium can be observed. This
paper will describe the simulation of these
changes in the mouse by the application of
3-4 benzopyrene and the SEM appearance of
the lesions produced. The cervices offemale
C3H mice were painted weekly with benzo-
pyrene, and groups of animals were killed
before treatment and following 4, 8, 16, 24,
32, 40 and 48 paintings. The cervices were
prepared for SEM examination and were
subsequently processed to produce histo-
logical sections. Surface changes-increases
in microvilli and disorganization of tissue
architecture-identical to those characteristic
of dysplasia and carcinoma in the human
cervix were seen, and increased in frequency
and abnormality with the number of applica-
tions of carcinogen.
CYTOPLASMIC DNA POLYMERASE
FROM RAT LIVER AND THE EFFECTS
OF CARCINOGEN TREATMENT.
J. G. SALISBURY and P. J. O'CONNOR,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester.
DNA polymerases from rat liver have
been studied in relation to their possible
involvement in the initiation of carcino-
genesis. Cytoplasmic DNA polymerase from
24-h regenerating liver, whether as a crude
extract, or after purification by phospho-
cellulose and DEAE cellulose chromato-
graphy, sedimented at 10 5S on glycerol
gradients with some activity (less than 10%
ofthe total) at 3 4S. High salt treatments of
the purified enzyme caused a reversible shift
of the major peak to 7S with no significant
increase in 3 4S activity. These results were
supported by the in vitro properties of the
untreated and treated enzymes. After treat-
ment in vivo with methylating carcinogens at
different times after partial hepatectomy,
gradient analysis ofcrude polymerase extracts
showed that production of the major com-
ponent was severely inhibited by early
treatment, with no change in molecular
species. Data suggest that the altered
level of 10-5S polymerase may be partly
responsible for the reduction of DNA
synthesis after carcinogen treatment.
PORPHYRINS IN THE URINE OF
RATS GIVEN DIETHYLNITROS-
AMINE. R. SCHOENTAL and S. GIBBARD.
Department of Pathology, Royal Veterinary
College and Department of Biochemistry,
Princess Alexandra Hospital, Harlow.
It has been suggested that alkylation of
coenzymes, including the haems, may be
responsible for the acute and subacute lesions
caused by hepatotoxins (Schoental, 1976,
FEBS Letters, 61, 111). Examination of the
urine of rats given diethylnitrosamine by the
method of Rimington (1971, Assoc. Clin.
Pathol. Broadsheet No. 70) showed increased
excretion of copro- and uroporphyrins. Other
hepatotoxins and their ability to cause
porphyria are being investigated, as well as
the mechanism by which porphyria isinduced.
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THE ADHESIVENESS AND TUMORI-
GENICITY, MALIGNANCY AND
INVASIVENESS WITHIN SYNGENEIC
HOSTS OF NORMAL AND VIRAL-
TRANSFORMED HAMSTER FIBRO-
BLASTS. R. G. P. PUGH-HUMPHREYS,
Cell and Experimental Pathology Unit, Depart-
ment of Zoology, Aberdeen University.
Decreased mutual adhesiveness is a
characteristic property of cells within many
invasive, malignant tumours (Abercrombie
and Ambrose, 1962, Cancer Res., 22, 525).
We investigated tumorigenicity of hamster
kidney (BHK21/C13) fibroblasts and their
polyoma virus transformants (Py-BHK)
(Stoker and MacPherson, 1964, Nature, Lond.,
203, 1355) within syngeneic hosts, as well as
malignancy and invasiveness of tumours
produced. Mutual adhesiveness of cells ob-
tained from solid tumours was determined in
aggregation assays in vitro (Curtis, 1973,
Prog. biophys. mol. Biol., 27, 317) and
compared with invasiveness of tumour cells
in vivo. Py-BHK cells were considerably
more tumorigenic than BHK21/C13 cells and
tumours produced by Py-BHK cells displayed
greater malignancy and host tissue invasion
than BHK21/C13 tumours. Py-BHK cells
were mutually less adhesive than BHK21/C13
cells and we consider that differences in
mutual adhesiveness ofthe two cell types may
partially explain observed differences in
invasiveness oftumoursproducedbyPy-BHK
and BHK21/C13 cells.
INDUCTION OF CONCANAVALIN
A AGGLUTINABILITY OF 3T3 CELLS
BY SV40-3T3 CELL PLASMINOGEN
ACTIVATOR. P. WHUR, H. KOPPEL,
C. URQUHART and D. C. WILLIAMS, Marie
Curie Memorial Foundation, Oxted, Surrey.
Plasminogen activator is found in cells
which have undergone malignant transforma-
tion, and certain malignant cell characteristics
have been linked to the activation of plasmi-
nogen to the protease plasmin. We have
therefore investigated the effects of plasmi-
nogen activation on the agglutinability of3T3
cells in concanavalin A. SV40-3T3 trans-
formants or conditioned medium were used as
sources of activator, and 3T3 cells aggluti-
nated extensively only when co-cultured with
SV40-3T3 cells or incubated in SV40-3T3
cell medium. This was due to plasminogen
activation by SV40-3T3 cells, since co-
cultured 3T3 cells agglutinated in serum-free
medium only in the presence of added
plasminogen. The existence of SV40-3T3
cell plasminogen activator was confirmed by
casein-agarose assay. These observations
suggest that normal tissue cells might
become " quasi-malignant " under the in-
fluence of plasmin activated by adjacent
malignant cells.
METABOLIC CHANGES IN LIVER
OF TUMOUR-BEARING ANIMALS.
R. A. McALLISTER, M. SOUKOP and K. C.
CALMAN, Department of Surgery, Western
Infirmary, Glasgow.
Previous results (Calman and McAllister,
1976, Br. J. Cancer in the press) with mice
bearing TLX-5 lymphoma, have shown that
decreases in the coenzyme A content of liver
occur at an early stage of tumour growth.
Later, when the animals were cachectic,
significant increases in the hepatic citrate
content occurred. This work has now been
extended with a C3H mammary tumour, and
Sarcoma 180. With C3H mammary tumour,
significant depressions (P < 0'001) of the
CoA content of liver occurred when the
tumours were small (mean wt. 16-1 mg) with
a concomitant increase in the citrate content
(P < 0.05). With Sarcoma 180, significant
depressions of the hepatic CoA content
occurred when the mean tumour weight was
0-92 g with no change in the citrate content.
In animals with a mean tumour weight of
4-27 g the CoA content of liver remained at a
low level, and significant increases (P < 0 02)
of the citrate content occurred. There were
also significant decreases in the pyruvate
(P < 0.05) andalpha-oxoglutarate(P < 0-01)
content of liver in these animals. It is
concluded that alterations in the levels of
CoA and citrate can occur at an early stage of
tumour growth, and that when the tumour
enlarges, further metabolic alterations in the
non-involved host liver occur.
TUMOUR CELL KINETICS FOLLOW-
ING CURATIVE HYPERTHERMIA
(420). S. K. CALDERWOOD and J. A. DICKSON,
Cancer Research Unit, Department of Clinical
Biochemistry, Royal Victoria Infirmary, New-
castle upon Tyne.
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Hyperthermia (420) selectively destroys
several types of cancer cell (Dickson and
Suzangar, 1974, Cancer Res., 34, 1263).
Yoshida sarcomas (1.5 ml) growing exponen-
tially on the hind feet of rats were cured by
an intratumour temperature of 42°C for 1 h.
These tumours had a doubling time of 36 h,
cell cycle time 14 1 h, growth fraction 75%0
and cell loss factor 0-62. Following heat,
there was an immediate 90%0 depression of
thymidine labelling and 60% depression of
mitotic rate. These parameters recovered to
control levels 48 h after heat, thereafter
declining to zero as the tumours completely
regressed within 14 days. The data imply a
rapid destruction ofproliferating cells by heat
and subsequent entry of non-proliferating
cells into cycle, followed by slow death of the
repopulating cells.
INDUCTION OF HYPERTHERMIA
IN RATS AND ITS EFFECT ON
PERIPHERAL BLOOD LEUCOCYTES.
J. M. GALT and A. E. WILLIAMS, Teaching and
Research Centre, Western General Hospital,
Edinburgh.
The role of immunity in mediating the
anti-tumour effects of whole body hyper-
thermia is being studied. A thermostatic
unit has been constructed to heat 6 anaesthe-
tized rats (or mice) by radiant heat. Body
temperatures from 37042' (+ 0-1)C have
been induced. An animal colonyfree ofchronic
respiratory disease isessential. Eightypercent
of rats survived 4h at 41 2°C. Above this
temperature mortality increased. Changes
in peripheral blood leucocytes and respon-
siveness of lymphocytes to PHA have been
monitored following periods of hyperthermia
or anaesthesia. Anaesthesia produced a
leucopenia followed by a granulocytosis and
a return to normal within 24 h. Hyper-
thermia produced a greater leucopenia,
especially in lymphocytes. Granulocytes in-
creased 2000 at 1 day and returned to normal
at 2 days. Lymphocytes were still depressed
at 3 days. Lymphocyte responsiveness to
PHA was depressed at 1 day following hyper-
thermia, but had returned to normal at low
PHA concentrations, by 3 days. Anaesthesia
controls showed essentially normal responses
to PHA at 1 and 3 days.
PRELIMINARY STUDIES ON THE
IMMUNOCOMPETENCE OF PA-
TIENTS UNDERGOING WHOLE
BODY HYPERTHERMIA THERAPY
FOR ADVANCED MALIGNANCY.
A. P. GEE, R. T. PETTIGREW, A. N. SMITH
and A. E. WILLIAMS, Teaching and Research
Centre and Departments of Anaesthetics and
Clinical Surgery, Western General Hospital,
Edinburgh.
The general immune status of 8 patients
with advanced gastrointestinal or genito-
urinary cancer has been monitored prior to,
during and following whole body hyper-
thermia. During treatment the absolute
number ofT cells in peripheralbloodincreased
in patients with responsive tumours (5) and
decreased significantly in the remainder (3).
In both groups T cell activity, as measured
by response to PHA, decreased at the end of
heating but increased the following day,
reaching a peak within a further 3 days and
returning to the pre-treament level within a
week Changes also occurred in numbers of
circulating B cells and in serum immuno-
globulin and complement levels, butthesedid
not show any clear trend. Although work is
still at an early stage, these results indicate
that hyperthermia therapy may induce a
small but favourable change in the responsive
patient's immune status at a critical time.
EFFECTS OF SERIAL PASSAGE ON
HUMAN TUMOUR XENOGRAFTS
GROWN IN IMMUNE-DEPRIVED
MICE. J. A. HOUGHTON and D. M. TAYLOR,
Department ofRadiopharmacology, Division of
Biophysics, Institute of Cancer Research,
Sutton, Surrey.
Assessment of the value of xenografts as
nodels for the study ofhuman cancerrequires
knowledge of any changes in characteristics
during successive transplants. Studies of
growth patterns and histological, histo-
chemical and biochemical parameters are
being made in successive passages of human
colorectal tumours growing in immune-
deprived CBA/LAC mice. The tumours,
which range from anaplastic to well-differen-
tiated, generally retain their histological
appearance throughout several transplant
generations, but one well-differentiated
tumour de-differentiated on primary passage.
Variation between tumour lines is marked,
but generally growth rate and percentage take
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increase in successive transplants. Human
LDH iso-enzyme patterns persist and sialo-
and sulphomucin production is under study.
Current results suggest that each tumour is
unique but that biochemical parameters do
not change markedly during early passages.
THE USE OF COLO-RECTAL XENO-
GRAFTS AS A MODEL SYSTEM FOR
CANCER CHEMOTHERAPY. K. NOWAK,
G. G. STEEL and M. J. PECKHAM, Radio-
therapy Research Department, Divisions of
Radiotherapy and Biophysics, Institute of
Cancer Research, Belmont, Surrey.
A series of human colo-rectal tumours
has been implanted and repeatedly passaged
in immune-suppressed mice. The immune
suppression has consisted of thymectomy
followed by whole-body irradiation and bone
marrow replacement. This study has at-
tempted to compare the response to chemo-
therapy of the xenografts with the clinical
course and chemotherapeutic response of the
patient from whom the grafts were taken.
The principal agents tested were 5 fluorour-
acil, methyl-CCNU and melphalan, but other
agentshave also beenused. The results have
shown that the effects of these agents can
readilybedeterminedbythe use ofregression-
regrowth data. It is clear that there is
considerable inter-patient variation in re-
sponse as determined by the xenografts.
There is some evidence, which we hope to
amplify, that the response of the xenografts
correlates with the response ofthe patient.
COMPARISON OF THE EFFECTS OF
5-FU AND SEX HORMONES ON A
METASTATIC CARCINOMA OF THE
COLON IN MAN AND ON THE
TRANSPLANTED TUMOUR IN IM-
MUNE-DEFICIENT MICE. C. R.
FRANKS, D. BIsHoP and H. G. STURZAKER,
Imperial Cancer Research Fund Breast Cancer
Unit, Guy's Hospital, London National In-
stitute of Biological Standards and Control,
London and Department of Surgery, Guy's
Hospital, London.
A metastatic carcinoma of the human
colon was transplanted to female thymecto-
mized irradiated mice. The tumour was
allowed to become established, following
which the tumour-bearing mice were treated
with 5-FU, or 5-FU and androgen, the
androgen being used as an immune poten-
tiator (Franks et al., 1975, Br. J. Cancer, 31,
100). The combination of drugs was found
to be marginally more effective than the
single agent. On the basis of the animal
study, the patient received a similar chemo-
therapy and hormone regime. Oestrogen
was used in preference to androgen, because
the patient was a male. Within 8 weeks of
starting treatment, there was clear evidence
that the progressive growth of the liver
metastases had stopped. Fifteen weeks after
starting treatment there had been a con-
siderable return to immune competence, as
measured by the patient's PHA response.
CLINICAL CHEMORESISTANCE AND
RADIORESISTANCE. T. B. BREWIN,
GlasgowInstitute ofRadiotherapeutics, Western
Infirmary, Glasgou.
The dose ofchemotherapy orradiotherapy
that can be given to a patient with cancer is
limited by unacceptable effects on normal
tissues. Therefore, what matters is not the
resistance ofthe malignant cells, but the ratio
between their resistance and that of normal
cells. This ratio varies in clinical practice,
but not to the extent that is sometimes
implied, and certainly much less than with
many experimental animal tumours. A
deterioration in this ratio in the course of a
patient's illness is often due more to decreased
normal cell resistance than to increased
tumour cell resistance. Unfortunately,
clinical chemoresistance correlates fairly
closely with radioresistance. Apart from cell
type, mitotic rate, differentiation and tumour
bulk, factors such as growth fraction, cell
loss, changes in oxygenation, and increased
rate of cell proliferation in surviving cells
have to be considered, while many exceptions
and paradoxes point to important unknown
factors.
ENHANCEMENT OF RADIOTHERA-
PEUTIC EFFECTIVENESS BY PI-
PERAZINEDIONE. M. B. GRIMSHAW,
G. E. MURKIN and K. HELLMAN, Depart-
ment of Cancer Chemotherapy, Imperial
Cancer Research Fund, Lincoln's Inn Fields,
London.
Resemblances in the chemical structures
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of piperazinedione (593A) and razoxane
(ICRF 159) as well as a similarity of action of
thetwocompounds ontumourneovasculature,
led to an examination to see if, like razoxane,
593A also potentiated the effects of radio-
therapy. 593A and radiation were first
tested on the radiosensitive Sarcoma 180 and
then on two relatively radioresistant tumours,
the B16 melanoma and the Lewis lung carci-
noma. Treatment was in the form of single
doses ofdrug andradiation oras the same total
dose split into 5 fractions given over 5 days.
No significant inhibition of tumour growth
was obtained with the B16 or 3LL tumours,
but 593A appeared to potentiate the inhibi-
tion of S180 by radiotherapy. Single doses
and fractionated treatment were equally
effective. When compared to some other
cytotoxic drugs combined with radiation on
the S180, 593A and ICRF 159 appeared the
most effective; however, the therapeutic
index for 593A is much lower than that of
ICRF 159.
INHIBITION OF GROWTH OF
LUNG METASTASES WITH COM-
BINED RADIATION AND ICRF 159.
H. A. ATHERTON, S. E. JAMES and K.
HELLMANN, Department of Cancer Chemo-
therapy, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London.
ICRF 159 ((+)-1,2-bis(3,5-dioxopiperazin-
1-yl)propane) is known to potentiate the
effect ofradiation on primary tumours in man
(Ryall et al., 1974, Cancer, 34, 1040), and it
thus seemed of interest to examine the effect
ofthis combination on pulmonary metastases
as a model for carcinoma of the bronchus.
The metastases were produced by the Lewis
lung carcinoma (3LL) implanted s.c. in the
flank. The primary tumour implants were
excised on Day 10 after inoculation and the
mice were given either radiotherapy alone
(500 rad whole lung) or radiotherapy in
combination with ICRF 159 (30 mg/kg) on
Days 14-18 inclusive. Combination therapy
increased the survival time of mice signi-
ficantly, but many early deaths not attribut-
able to lung secondaries occurred. Oxytetra-
cycline (10% Terramycin) given with com-
bination therapy greatly prolonged the
survival timne and may itself have some anti-
metastatic activity.
2.)
COMBINED EFFECT OF ICRF 159 AND
X-RAYS ON A MOUSE TUMOUR
CELL LINE GROWN IN VITRO
I. TAYLOR and N. M. BLEEHEN, MRC
Clinical Oncology and Radiotherapeutics Unit,
The Medical School, Hills Road, Cambridge.
ICRF 159 potentiates X-ray lethality in
experimental animal tumours (Hellman and
Murkin, 1974, Cancer, 34, 1033; Norpoth
et al., 1974, Z. Krebsforsch., 82, 329), but not
in HeLa, following a short in vitro drug
exposure (Dawson, unpublished). After 24 h
exposure in vitro to 200 jug/ml of ICRF 159,
exponentially growing EMT6 cells showed
radiosensitization. The potentiation effect
was seen to decrease as the cultures pro-
gressed from exponential growth (pulse
thymidine labelling index = 550%) to a
plateau phase of growth (labelling index=
<10%) and was also found to be dose- and
time-dependent. Cellular DNA analysis by
flow cytofluorimetry indicates a relationship
between DNA content and the radiation
potentiation effect.
RECOVERY FROM RADIATION
DAMAGE MEDIATED BY SOMATIC
CELL HYBRIDIZATION. J. M. BOYLE,
A. R. KINSELLA and P. J. SMITH, Paterson
Laboratories, Christie Hospital and Holt
Radium Institute, Manchester.
Intraspecific hybridization between Chi-
nese hamster lines Wg3h (hypoxanthine
guanine phosphoribosyl transferase deficient,
HGPRT-) and A23 (thymidine kinase de-
ficient, TK-), and interspecies hybridization
between Wg3h and mouse 3T34E (TK-) were
used to study the radiation survival of com-
plementing phenotypes by hybrid selection
in HAT medium. The fusion process per se,
as determined by heterokaryon frequency,
was not affected by the radiation doses
employed. When only one of the two
parent lines was X-irradiated prior to hybri-
dization, the hybrid survival curve approxi-
mated to single hit kinetics with a zero dose
extrapolation (n) of 1-0 ± 0-1. The ratio,
Do hybrid formation: Do parent c.f.u. was
approximately 4. " Mutual Rescue " by
hybridization of two parent lines that had
received isodoses of X-rays, contributed
significantly to hybrid survival when proper
consideration was given to feeder layer
effects, the major effect being an approxi-
mately two-fold increase in n.
315B.A.C.R. 17TH ANNUAL GENERAL MEETING
INHIBITION OF TUMOUR GROWTH
IN RATS SENSITIZED TO RAT
FOETAL ANTIGENS. R. C. REES and
L. P. SHAH, Cancer Research Campaign
Laboratories, University of Nottingham.
Multiparous rats and rats immunized
with cells or tissue derivedfrom 14-15-day-old
rat embryos have been shown to possess
lymphoid cells reactive towards tumour-
associated antigen(s). Although cytotoxicity
can be demonstrated readily in vitro, in vivo
immunization using rat embryonic tissue has
failed to induce a strong rejection response
to s.c. tumour challenge. However, following
i.v. inoculation of rat tumour cells into rats
immunized against rat embryonic tissue, a
reduction in the growth of pulmonary tu-
mours has been found, compared with
controls. Further investigation has shown
that rats immunized by embryoma excision
or with irradiated (5000 rad) embryo cells, in
addition to multiparous rats, are able to limit
tumour growth in this way. The specificity
ofthis reaction has been studied by using cell
membrane preparations derived from various
tissues, and membranes prepared from 15-
day-old rat embryos were shown to give the
best protection against pulmonary tumour
development. This in vivo assay may prove
a more sensitive technique for the detection
of in vivo immune responses against tumour-
associated embryonic components.
IMMUNIZATION WITH SOLUBI-
LIZED EXTRACTS OF RAT TU-
MOURS AND FRACTIONS OF
TUMOUR-BEARER SERUM. M. R.
PRICE, V. E. PRESTON and M. ZOLLER,
Cancer Research Campaign Laboratories, Uni-
versity of Nottingham and D.K.F.Z., Heidel-
berg, Germany.
Soluble fractions retaining tumour anti-
genic activity were prepared from 3-methyl-
cholanthrene-induced rat sarcomata by 3M
KCI treatment of tumour tissue. These
fractions were evaluated in an immunoprotec-
tion assay whereby rats received 3 weekly
i.p. injections of tumour extract followed by
s.c. challenge with viable tumour cells 7 days
after the final injection. All preparations
were examined for immunogenicity over a
wide antigen dose range. Optimal protec-
tion, as indicated by survival, tumour inci-
dence and rate of tumour development, was
evident only in rats receiving treatment
within a limited antigen dose range, whereas
tumour enhancement was occasionally ob-
served at high antigen concentrations. Sepa-
ration of rat sarcoma-bearer serum by gel
filtration column chromatography, under
conditions designed to isolate tumour-specific
antigen, antibody and immune complexes
was performed, and these fractions were
evaluated for immunogenicity in the immuno-
protection assay. The findings are related to
the nature of tumour-specific antigens as
immunogens and to the possible contributions
of serum factors in modifying cellular re-
sponses in the tumour-bearing host.
CHARACTERIZATION OF THE
SERUM FACTORS WHICH MODU-
LATE SPLENIC CYTOTOXICITY IN
A SYNGENEIC RAT TUMOUR
SYSTEM. N. MATTHEWS, P. J. CHALMERS
and R. C. NAIRN, Department ofPathology and
Immunology, Monash Medical School, Mel-
bourne, Australia.
In Wistar rats bearing a syngeneic
squamous cell carcinoma (Spl), in vitro
anti-tumour cytotoxicity by splenic T lym-
phocytes can be detected 4 weeks after
tumour inoculation and persists until death
after 8 weeks. Cytotoxicity is blocked by
sera taken after 6-8 weeks of tumour growth
and this effect is expressed at the tumour cell
and not at the T lymphocyte level. At an
earlier stage in tumour growth (4-6 weeks)
sera can induce in vitro anti-tumour cyto-
toxicity by non-immune splenocytes. Thus,
at different stages of tumour growth, two
functionally distinctive serum effects are
observed. Serum fractionation by ion-ex-
change chromatography using DEAE-cellu-
lose has shown that blocking activity is
located in the fraction containing IgG2a'
while the capacity to induce anti-tumour
lymphocytotoxicity is found in the fraction
containing IgG2b and IgG1.
INHIBITION OF CELL-MEDIATED
IMMUNITY TO RAT SARCOMAS
FOLLOWING TREATMENT WITH
ISOLATED TUMOUR ANTIGEN
PREPARATIONS. M. J. EMBLETON,
Cancer Research Campaign Laboratories, Uni-
versity ofNottingham.
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Inbred Wistar rats were pretreated with
extranuclear membrane fractions or 3M
KCl-solubilized tumour membrane extracts
of two antigenically distinct 3-methylehol-
anthrene-induced sarcomas, Mc7 and Mc57.
The pretreated animals failed to develop
resistance to challenge with the same tumour
and were also unresponsive to subsequent
immunization with irradiated tumour grafts,
a procedure which induces tumour rejection
in normal rats. This effect was tumour-
specific since Mc7 extracts induced un-
responsiveness to Mc7-irradiated grafts, but
allowed successful immunization against Mc57
and vice versa. In vitro studies revealed a
lack of cell-mediated cytotoxicity in antigen-
treated rats, although they developed a
humoral antibody response against the
respective tumour. Antigen-treated rats had
both serum blocking factors and suppressor
lymphoid cells, which it is postulated were
responsible for the depressed state of cell-
mediated tumour immunity.
ADJUVANT CONTACT SUPPRESSION
OF RAT AND HUMAN TUMOURS
IN ATHYMIC NUDE MICE. M. V.
PIMM, Cancer Research Campaign Labora-
tories, University of Nottingham.
Previous studies (Nature, Lond., 1975,
254, 77) have demonstrated that growth of
rat tumour xenografts in athymic (nude)
mice can be suppressed by injection in
admixture with BCG organisms, suggesting
that T-lymphocyte-mediated responses are
not essential for adjuvant contact therapy
with this agent. These stidies have been
extended to examine the contact suppression
effect in athymic mice of other microbial
adjuvants known to be effective in syngeneic
hosts. Comparable to the finding with BCG,
Corynebacteriumparvum injectedintoathymic
mice in admixture with cells ofrat sarcomata
and hepatomata suppressed their develop-
ment, and mice rejecting mixed inocula were
not immune to further challenge. Silica
pre-treatment of mice, which abrogated BCG
contact therapy, did not, however, affect
C. parvum contact suppression. In contrast,
fungal virus double-stranded RNA failed to
suppress tumours in athymic mice, although
this agent prevents growth in syngeneic rats.
Tests have also been initiated to examine
adjuvant contact therapy against human
tumour xenografts in athymic mice, and so
far it has been established that growth ofcells
from a human bladder carcinoma line (T24)
can be prevented by admixture with BCG.
THE MEM TEST. CLINICAL PO-
TENTIAL FOR THE EARLY DETEC-
TION OF CANCER. J. A. V. PRITCHARD,
Tenovus Laboratories, Velindre Hospital,
Whitchurch, Cardiff.
The macrophage electrophoretic mobility
(MEM) test was first described by Field and
Caspary (1970, Lancet, ii, 1337). This test
has been confirmed by several laboratories
(Pritchard et al., 1972, Lancet, ii, 627;
Goldstone et al., 1973, Clin. exp. Immunol.,
14, 469; Preece and Light, 1974, Clin. exp.
Irnmunol., 18, 543). From the examination
of clinical data two important facts emerge.
Firstly, the ability of the test to discriminate
between a cancer population and a control
population without overlap. A series of 105
patients with non-malignant disease resulted
in 13 unexplained positive results. These
13 results showed a sex and age distribution
in agreement with figures predicted from
cancer registration statistics if the MOD-
MEM test detected cancer about 16 years
before the clinical appearance of the disease.
Secondly the false negative rate for the
MEM test is extremely low: 1 in 500. This
suggests that the test can now be used with
confidence for the exclusion of malignant
disease.
REPLICATION OF EB VIRUS IN
MALIGNANT EPITHELIAL CELLS
FROM NASOPHARYNGEAL CARCI-
NOMA (NPC). P. A. TRUMPER and
M. A. EPSTEIN, University Department of
Pathology, Medical School, Bristol.
NPC material was passaged in nude mice
to eliminate non-malignant infiltrating cells.
The derivation of the mouse tumours from
human NPC malignant epithelial cells was
confirmed by cytogenetics, electron micro-
scopy and immunofluorescence tests. On
culture, these tumours gave monolayers of
epithelial cells containing keratin and desmo-
somes and expressing EB virus nuclear
antigen; no EB virus particles were present.
However, in such epithelial cell cultures
317B.A.C.R. 17TH ANNUAL GENERAL MEETING
treated with BUdR a herpes virus was seen
by electron microscopy, and immunofluores-
cence tests for virus capsid antigens with a
battery ofhuman sera identified this agent as
EB virus. EB virus has thus, for the first
time, been activated in NPC epithelial cells,
and shown to be capable of replication in a
cell type other than a primate B lymphocyte.
IMMUNOGLOBULIN RECEPTORS ON
LEUCOCYTES FROM PATIENTS
WITH ACUTE MYELOID LEUKAE-
MIA. G. M. TAYLOR, J. C. RIDWAY,
R. HARRIS and C. B. FREEMAN, Department
of Medical Genetics, St Mary's Hospital,
Manchester.
Immunoglobulin receptors on normal and
acute myeloid leukaemic leucocytes were
detected by rosette formation with anti-
Rhesus-antibody-coated human erythrocytes
(HEA). The efficiency ofrosetting depended
upon the source of the anti-Rh sera, the
Rhesus genotype of the human erythrocytes
and the source of the test leucocytes. AML
leucocytes, particularly from myelomonocytic
leukaemias fornmed higher percentages of
rosettes than normal leucocytes or granulo-
cytes. The AML HEA-rosette-forming cells
(RFC) were blast ormonocytic inmorphology.
Pronase, at a concentration having little
effect on normal lymphocyte HEA-RFC,
markedly increased the ability of certain
AML leucocytes to form rosettes. Using
normal and pronase-treated AML cells an
inverse correlation was found between HEA
rosetting and surface Ig staining, suggesting
that immunoglobulin blocks Fe receptors on
AML leucocytes. Moreover, HEA rosetting
by AML leucocytes was strongly inhibited by
normal and AML sera and by human
y-globulin but not by albumin. Thus, the
characteristic surface immunoglobulin of
acute myeloid leukaemic cells may in fact be
y-globulin aggregates or immune complexes
bound to immunoglobulin (Fc) receptors.
NEW THOUGHTS ABOUT THE
PHILADELPHIA CHROMOSOME. S.
D. LAWLER, Department of Cytogenetics and
Immunology, Division ofMedicine, Institute of
Cancer Research and The Royal Marsden
Hospital, London.
In 1973 Rowley (Nature, Lond., 243, 240)
showed that the material deleted from the
Philadelphia chromosome (Ph1) is trans-
located on to a number 9 (Ph1-t). Alterna-
tives to the regular Ph1-t have been described,
the frequency at the Royal Marsden Hospital
being 1/44. Concomitant with cytogenetic
advances there has been a newr approach to
cell classification in leukaemia (Minowada
et al., 1972, J. natn. Cancer Inst., 49, 891).
Patients with the Ph'-t in blast crisis of
chronic myeloid leukaemia can have cell
surface markers of acute lymphoblastic
leukaemia (ALL) (Janossy et al., in prepara-
tion), and the presence of Ph1-t in the T cells
of a child with ALL (Walker and Hardy,
1975, Lancet, ii, 1301) has been described.
So the restriction of the Ph' chromosome to
cells of myeloid origin is no longer an article
of faith.
THE PATTERN OF INFECTION IN
ACUTE MYELOGENOUS LEUKAE-
MIA (AML). P. F. M. WRIGLEY, J. S.
TOBIAs and F. W. O'GRADY, The ICRF
Department of Medical Oncology, St Bartho-
lomew's Hospital and Hackney Hospital and
Department of Bacteriology, University of
Nottingham.
Since infection is the chief cause of death
in acute leukaemia. 165 consecutive patients
with AML were studied with regard to: (i)
frequency of infections; (ii) bacteriology;
(iii) response to antibiotic regimes; (iv)
influence of infection on prognosis; and (v)
importance ofempirical antibacterialtherapy.
Presence of fever at the time of admission to
hospital was accompanied by a worse prog-
nosis (afebrile, 73%0 remission; febrile, 27%
remission). Only 3 patients did not become
febrile during remission induction. 265
positive bacteriological cultures were ob-
tained; bacteraemia was present in 37 of
these. Pseudomonas and Klebsiella were the
commonest bacteraemic pathogens, although
E. coli was the most frequent organism
cultured from all sites (78). The commonest
empiric antibiotic regimes were (success
rate): 1971 chloramphenicol/erythromycin
(52%); 1972 polymyxin B/flucloxacillin
(540 ); 1973 gentamicin/cephaloridine (56%);
1974 gentamicin/carbenicillin (61%); and
1975 tobramycin/carbenicillin (64%).
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CHANGES IN NON-SPECIFIC LYM-
PHOCYTOTOXICITY PRODUCED BY
BCG VACCINATION OF CANCER
PATIENTS AND NORMAL VOLUN-
TEERS. N. THATCHER, N. CGASIUNAS and
D. CROWTHER, Department of Medical On-
cology, Christie Hospital and Holt Radittm
Institute, Manchester.
Healthy volunteers (5) and patients with
metastatic malignancy (9) from the follow-
ing primaries (malignant melanoma 5, hyper-
nephroma 3, and colon carcinoma) were
studied. No patient had received previous
systemic treatment prior to this investigation.
The BCG (Glaxo) was given by Heaf gun, 5
applications per limb and blood samples
taken before, and on Days 2, 4, 7, 10, 21, 28
after vaccination. The assay system em-
ployed the reaction of 5'Cr-labelled Chang
cells with subjects' lymphocytes alone-
direct cellular cytotoxicity (DCC); with
lymphocytes and rabbit anti-Chang serum-
antibody-dependent cellular cytotoxicity
(ADCC); and with lymphocytes stimulated
by PHA-PHA-induced cytotoxicity (PC)
(Holm and Perlmann, 1967, J. exp. Med.,
125, 72; MacLennan and Loewi, 1968,
Nature, Lond., 219, 1069. A consistent pattern
of cytotoxicity was found in both volunteers
and patients. At Day 2 a decrease in
ADCC and PC (and also DCC in patients)
was observed followed by an "' overshoot "
above Day 0 values in DCC, ADCC and
PCC at Day 7 and 10 which declined to
pre-BCG levels over the next 2-3 weeks.
Those patients who partially responded to
BCG therapy tended to behave like the
normal volunteers, with greater overshoots
and smaller " negative " phases, compared
with those patients with progressive disease.
The assay would appear to test both T
lymphocytes (PC) and non-T lymphocyte
function (ADCC) (Hersey, Edwards and
Edwards, 1976, Clin. exp. Imrnunol., 23, 104)
and describes changes in lymphocytotoxicity
follow%ing immunotherapeutic endeavours.
INHIBITION OF E-ROSETTE FOR-
MATION BY SERA FROM CANCER
PATIENTS. R. H. WHITEHEAD, G. P.
ROBERTS, J. THATCHER, C. TEASDALE and
L. E. HUGHES, University Department of
Surgery, Welsh National School of Medicine,
Cardiff.
It has been shown that the percentage of
E-rosetting cells is decreased in patients with
carcinoma of the breast. Treatment of
lymphocytes from cancer patients by mild
enzyme (papain) digestion increases E-
rosetting counts to normal levels. Re-incu-
bation of these treated lymphocytes in auto-
logous serum abrogates this effect and
restores E-rosetting cell levels to pre-papain
values. Incubation of lymphocytes from
normal controls in sera from cancer patients
also causes depression of the E-rosetting cell
levels and this depression can be reversed by
papain treatment. Incubation in normal
allogeneic sera has less effect on E-rosetting
cell levels. Fractionation studiesofinhibitory
sera on G200 have shown that the inhibitory
factor is of high molecular weight. These
findings would suggest that there is a tumour
product present in the serum of cancer
patients which nonspecifically masks the
E-receptor sites on a proportion ofT-lympho-
cytes. This (and other evidence) suggests
that there are at least two sub-populations
of human T-lymphocytes which is masked
by this factor.
LEVAMISOLE-A DOUBLE BLIND
IMMUNOLOGICAL STUDY. D. J. T.
WEBSTER and L. E. HUGHES, University
Department ofSurgery, Welsh National School
of Medicine.
Levamisole has been widely reported as
having immunopotentiating activity in both
man and animals. This paper presents the
preliminary findings of an ongoing double-
blind assessment of levamisole. Patients
with advanced carcinoma of breast, colon,
stomach or melanoma have been assessed by
immunological parameters. The tests used
are DNCB and Mantoux responses, totalwhite
cells and lymphocyte counts, lymphocyte
stimulation by PHA and measurement of
immunoglobulin classes G, A and M. Thirty-
six patients have been analysed-17 leva-
misole and 19 placebo. No significant
differences have been seen in any of the
measured parameters when measured 1, 2, 3
and 6 months after a course of treatment
(levamisole 3 x 150 mg/week for 4 weeks).
The most frequent side-effect was giddiness,
which was recorded in 5/17 patients on
levamisole. There is no support in this trial
for an immunopotentiating effect of leva-
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misole in cancer patients, although larger
numbers of patients require study to reach
statistical significance.
A STUDY OF THE PHARMACO-
KINETICS OF P-HYDROXYANILINE
MUSTARD, CHLORAMBUCIL,
PHENOL AND PHENYL PHOSPHATE
BY HIGH-PRESSURE LIQUID CHRO-
MATOGRAPHY (HPLC). P. WORK-
MAN, J. A. DOUBLE and C. R. BALL, Depart-
ment of Cancer Research, University of Leeds.
Simple rapid analytical methods for the
determination of p-hydroxyaniline mustard
(AMOH), chlorambucil, phenol and phenyl
phosphate in biological materials by HPLC
have been established. Only verylowplasma
concentrations are detectable following a
supra-lethal dose of AMOH in mice, whereas
chlorambucil disappears less rapidly (plasma
half-life 70 min). The pharmacokinetics of
phenol and phenyl phosphate were studied
as model compounds for AMOH and p-
hydroxyaniline mustard phosphate (AMO-
phos) respectively. This work has shown (1)
that phenol has a short plasma half-life
(10 min) and (2) that phenyl phosphate is
rapidly hydrolysed to phenol, which is
detectable in high levels in plasma and
tissues. This suggests that the activity of
non-tumour phosphatases may negate the
potential selective effect of AMO-phos on
tumours possessing highphosphataseactivity.
THE CLINICAL PHARMACOLOGY
OF CB 10-252 IN HEPATOMA PA-
TIENTS. M. H. N. TATTERSALL and G. A.
CURT, Department of Medical Oncology,
Charing Cross Hospital, London.
CB 10-252 is a latent, tissue-activated
alkylating agent developed for treatment of
hepatocellular carcinoma (Bukhari et al.,
1973, J. natn Cancer Inst., 50, 243). Hepa-
toma and normal liver cells contain azore-
ductase activity, which converts CB 10-252
into an active alkylating radical (Autrup and
Warwick, 1973, 1IthInt. Cancer Cong., 2, 137).
The active alkylating radical hydrolyses with
a T' of 45 s. This approximates the hepatic
circulation, and CB 10-252 activated in the
liver should be hydrolysed before reaching
the systemic circulation and myelosuppres-
sion should not occur. An in vitro assay was
developed to measure azoreductase activity
in human tissue specimens. Human liver
azoreductase activity was 4222 ± 500 nM
drug reduced/g protein/15 min, bone marrow
was 2437 + 5%, human spleen 2513 + 5%,
and cultured human liver cells in log phase
growth 2641 + 500. Serial urine collected
from 3 patients on 30 mg CB 10-252 daily
showed that 80% of the drug was activated
and excreted in 8 h. Trace amounts (2-5
nM/ml) of inactivated drug were identified in
the plasma at this time. Rat liver, with
nearly twice human azoreductase activity
(8213 i 5%), clears plasma of a 10 mg/kg
i.p. injection within 2 h. Thus human
hepatic enzyme activity restricts a first pass
phenomenon and marrow activation of circu-
lating drug explains myelosuppression ob-
served in patients receiving the drug.
HUMAN PHARMACOLOGY OF
METHOTREXATE. A. H. CALVERT and
K. R. HARRAP, Department of Applied
Biochemistry, Institute of Cancer Research,
Sutton.
Methotrexate (MTX) is a widely used
anticancer drug, whose toxicity, both to
normal and tumour cells, isproportionaltothe
time of exposure to the drug (Goldie, Price
and Harrap, 1972, Eur. J. Cancer, 8, 409).
Hence the pharmacokinetics in man is an
important determinant of both toxicity and
therapeutic effect. Assays by the method
of Bertino and Fischer (Methods in Medical
Research, 1964; 10, 297) reveal a biphasic
plasma decay curve with halflives ofapproxi-
mately 0 5 and 6 h following i.v. or i.m.,
dosage. Renal clearance correlates well with
glomerular filtration rate (GFR) and is
0-6 x GFR. Plasma clearance is about 2 x
GFR. The parameters for a two-compart-
ment model have been derived from these
data. A method to determine the degree of
inhibition ofdihydrofolate reductase (DHFR)
in tissues has been developed, in an attempt
to see whether > 95% inhibition corresponds
with clinical response. This result would be
expected from previous work (Jackson and
Harrap, 1973, Arch. Biochem. Biophys., 158,
2; Harrap and Jackson, 1975, Advances in
Enzyme Regulation, 15, 77). Provisional
data from this method indicate that a plasma
MTX level of 10-7M achieves only 30°/O
saturation of DHFR in breast carcinoma
tissue.
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THE PROTECTION OF NORMAL
TISSUES FROM METHOTREXATE
TOXICITY. D. C. TALBOT, J. A. STRAW,
G. A. TAYLOR and K. R. HARRAP, Depart-
ment of Applied Biochemistry, Institute of
Cancer Research, Sutton.
The requirements for protectioin against
methotrexate (MTX) toxicity with preformed
purines and pyrimidines have been studied
in several mammalian tumour cell lines
(Tattersall et al., 1974, Eur. J. Cancer, 10,
819). The aim of the present study was to
determine the rescue characteristics ofnormal
proliferating tissues in order to optimize
MTX treatment protocols. Male DBA2/
C57BLF1 hybrid mice given lethal doses of
MTX (400 mg/kg i.p.) survived when treated
with thymidine, hypoxanthine and allo-
purinol (500, 50, 10 mg/kg i.p., thrice daily
for 5 d4ys), but were not rescued either with
mixtures of hypoxanthine + allopurinol, or
with thymidine alone. Mice bearing L1210
leukaemia were rescued by thymidine, indi-
cating the ability of normal tissues to utilize
low levels ofpurines released from autolysing
tumour cells. MTX treatment induced an
early purine deficiency in gut (but not
marrow), though by 24 h deficiency of
purine and pyrimidine was established in
both tissues. These observations are of
significance in relation to the selective protec-
tion of normal tissues.
THE TOXICITY OF ADENOSINE TO
LYMPHOID CELLS AND ITS PO-
TENTIATION. K. R. HARRAP, R. M.
PAINE and J. F. SMYTH, Department of
Applied Biochemistry, Institute of Cancer
Research, Sutton.
The identification of a severe combined
immunodeficiency syndrome associated with
adenosine deaminase (ADA) deficiency (Dis-
sing and Knudsen, 1972, Lancet ii, 1316) has
focussed attention on the toxicity of adeno-
sine to lymphocytes and the possible protec-
tive role of ADA. The particularly high
level of ADA in human malignant lympho-
cytes may be therapeutically exploitable
(Smyth, and Harrap, 1975, Br. J. Cancer, 31,
544). The molecular basis of adenosine
toxicity has been explored in both trans-
plantable lymphoid tumour cells and in
cultured human lymphocytes stimulated with
PHA. In the former case adenosine induces
imbalanced synthesis of nucleic acid and
protein, while in the latter the onset of DNA
synthesis is delayed. In both cases the
effects of adenosine are markedly poten-
tiated by coformycin, a tight-binding in-
hibitor of ADA. It is possible that combina-
tions of adenosine + coformycin may have
use, both in the treatment of acute lympho-
blastic leukaemia, and in immunosuppression.
POSSIBLE MECHANISM UNDER-
LYING THE SELECTIVE ANTI-
TUMOUR EFFECT OF LEO 1031.
R. WILKINSON, E. D. GILBY, I. KONYVES and
K. R. HARRAP, Department of Applied Bio-
chemistry, Institute of Cancer Research, Sutton,
and the Research Laboratories, AB Leo,
Hdlsingborg, Sweden.
Leo 1031, a prednisolone-21 ester of
chlorambucil, has been shown to be less
myelotoxic than chlorambucil in both animal
experiments and in clinical trials. It also
has increased antitumour activity, giving a
70% killofalkylating-agent-resistant Yoshida
sarcoma cells, and is more effective than
chlorambucil against the sensitive Yoshida
line. In vitro, Leo 1031 binds to a serum
protein and is released as prednisolone and
chlorambucil after hydrolysis by a serum
esterase enzyme. Human bone marrow cells,
human leukaemic blast cells and transplant-
able tumour cells alsohydrolyse Leo 1031, but
at different rates. The rate of hydrolysis in
tumour cells is generally faster than in normal
bone marrow or serum. This could explain
the low myelotoxicity compared with chlor-
ambucil and underlie the selective antitumour
effect of Leo 1031 in vivo.
QUANTIFICATION IN SITU OF
TUMOUR RESPONSE TO CHEMO-
THERAPY. P. J. HOUGHTON and D. M.
TAYLOR, Department of Radiopharmacology,
Division of Biophy'is.cs, Institute of Cancer
Research, Sutton.
A simple rapid method for the quantifica-
tion of tumour response to chemotherapy in
situ has been developed using the Lewis lung
tumour and B16 melanoma in mice. This
assay, based on changes in fractionation
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incorporation (FI) of 3H-thymidine into
DNA, permits the calculation of an " Equi-
valent Repopulating Fraction" (ERF) from
observations at a single time point after drug
treatment. In these two tumours the ERF
values agree well with the surviving fractions
determined by clonogenic cell assays in vitro.
This method appears to have general applica-
bility to any tumour system for which the
tumour doubling time can be measured and
it is currently being tested in human tumour
xenografts. In one such tumour, a moder-
ately differentiated rectal adenocarcinoma,
cyclophosphamide (200 mg/kg) produced a
marked, but transient, depression of FI and
the calculated ERF was 0-5 suggesting that
the tumour was relatively resistant to this
agent.
RESPONSE OF THE EMT6 MOUSE
TUMOUR TO CYCLOPHOSPHAMIDE
-A COMPARISON OF RESULTS
OBTAINED USING GROWTH CURVE
DATA AND THE IN VITRO
PLATING TECHNIQUE. P. R.
TWENTYMAN, MRC Clinical Oncology and
Radiotherapeutics Unit, The Medical School,
Hills Road, Cambridge.
Following treatment of EMT6 solid
tumours with cyclophosphamide at a volume
of either 50 or 300 mm3, a growth delay of
around 3 days per 100 mg/kg (in the range
0-300 mg/kg) is produced. Results of an
experiment measuring time to reach a given
tumour volume following various inocula
indicate a minimum tumour doubling time of
20-22 h. The greatest reduction in surviving
fraction compatible with a growth delay of 3
days is therefore around a factor of lOx for
each 100 mg/kg. Experiments in which cell
suspensions are prepared from treated tu-
mours and plated out in vitro indicate
surviving fractions which are lower than this.
Examination of changes in measured sur-
viving fraction over the first 48 h after
treatment strongly suggest that the operation
of " recovery frompotentiallylethaldamage "
may explain these discrepancies. Experi-
ments on tumours treated whilst still at the
undetectable stage indicate that the growth
delay for a given dose of cyclophosphamide is
increased, and therefore that the reduction
in surviving fraction is probably more severe
in these sub-clinical tumours.
COLLATERAL SENSITIVITY
STUDIES BETWEEN HALOGENATED
METHOTREXATES AND AN ALKYL-
ATING AGENT. B. W. Fox and D. J.
PILLINGER, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester.
A few examples of collateral sensitivity
have now been described in mammalian
tumour cell lines. The phenomenon, ori-
ginally observed in bacterial systems, de-
scribes the simultaneous sensitization of a
tissue to one drug on acquiring resistance to
another. Most reported examples have been
demonstrated in whole animals, and may
thus be influenced by changes in the host.
Furthermore, the few recorded instances have
been associated primarily with resistance
towards antimetabolites. In the work to be
presented, an example of collateral sensi-
tivity towards halogenated methotrexates of
tumours resistant to an alkylating agent,
methylene dimethane sulphonate will be
described. In this system, collateral sensi-
tivity, observed in whole animal studies, is
maintained when the tumours are grown in
culture as continuous cell lines. The level
ofdihydrofolate reductase has been measured
in these cell lines and the possible origin ofthe
collateral sensitivity will be discussed.
THE EFFECT OF CYCLOPHOS-
PHAMIDE AND METHOTREXATE
ON "SALVAGE" AND DE NOVO
DNA SYNTHESIS. K. D. TEW and D. M.
TAYLOR, Radiopharmacology Dept., Institute
of Cancer Research, Sutton.
After single-dose methotrexate (MTX) or
cyclophosphamide (CY) treatment the uptake
of 3H-thymidine (salvage), 3H-deoxyuridine
(de novo thymidine) and '4C-formate (de novo
thymine and purines) has been monitored in
the BICR A15 rat tumour as compared to gut
and bone marrow. Treatment with 100 mg/kg
CY has shown a potentially exploitable
time differential between recovery of vital
tissues (3-5 days) and tumour (> 10 days).
Methotrexate has been shown to exert its
cytotoxic effect by depleting de novo thymine
production rather than de novo purine
synthesis. This can be linked biochemically
with the ability of the latter pathway to
recycle tetrahydrofolic acid and overcome
the MTX block. Tumour cells efficient in
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salvaging thymidine, can overcome the " de
novo" thymine block more effectively than
gut cells-a fact which may limit the thera-
peutic usefulness of MTX.
OBSERVATIONS ON THE PREVEN-
TION OF CYCLOPHOSPHAMIDE-
INDUCED CYSTITIS. D. A. TOLLEY
and J. E. CASTRO, Urological Unit, Royal
Postgraduate Medical School, Hammersmith
Hospital, London.
The clinical use of cyclophosphamide may
be severely limited by its toxic effects on the
urinary bladder (Spechter et al., 1965, Dtsch.
med. Wschr., 20, 1458). We have developed
a laboratory model in the rat in which these
toxic phenomena are consistently reproduced.
The effects of N-acetylcysteine on the pre-
vention and treatment of cyclophosphamide-
inducedcystitiswere studied, andourobserva-
tions showed that N-acetylcysteine was
effective in the prophylaxis and early treat-
ment of this condition. The results of
cyclophosphamide and N-acetylcysteine
therapy on peripheral white count, spleen
morphology and weight showed that the
effect of combined therapy and cyclophos-
phamide alone were identical. Such obser-
vations suggest that N-acetylcysteine does
not interfere with the cytotoxic effects of
cyclophosphamide.
MECHANISTIC STUDIES WITH A
CELL LINE RESISTANT TO ICRF
159. K. WHITE and A. M. CREIGHTON,
Imperial Cancer Research Fund, Lincoln's Inn
Fields, London.
A line of BHK21S cells has been isolated
which shows resistance to the anti-tumour
agent ICRF 159, and has been designated
BS/159-1. The resistance index ofBS/159-1
cells is 40 as determined by in vitro survival
assays. Resistant cells have similar growth
characteristics to the sensitive parent line.
The resistance is not due to decreased uptake
or altered metabolism of the drug. In
contrast to the sensitive line, BS/159-1 cells
enter mitosis at the normal rate, and have
discretely condensed chromosomes when
treated with doses ofICRF 159 up to 100 ,ug/
ml. At higher doses, characteristic toxic
effects are seen. Studies with a wide variety
of cytotoxic agents (using in vitro survival
assays) show the same degree of cross
resistance only to structural analogues of
ICRF 159. A smaller but consistent cross
resistance to adriamycin and daunomycin
was demonstrated.
CHEMOTHERAPY AS PRIMARY
TREATMENT FOR SMALL CELL
CARCINOMA OF THE LUNG. P. K.
BONDY and E. D. GILBY, Biology of Human
Cancer Unit, Ludwig Institute for Cancer
Research, Royal Marsden Hospital, London.
Sixty-one patients with small-cell carci-
noma were treated with a 5-drug chemo-
therapy schedule given every 4 weeks.
Tumour regression to at least 50% of pre-
treatment size occurred in 60% of cases. All
patients also received radiotherapy. The
survival of chemotherapy responders was
significantly greater (median 44 weeks) than
that of non-responders (median 19 weeks).
No difference in median survival was seen
between patients treated initially with radio-
therapy and those in whom it was deferred
until afterthe second course ofchemotherapy,
but it was frequently impossible to assess
responsiveness to drugs after radiotherapy.
Since the median survival of all patients
studied was not significantly greater than
that of a group treated by deep X-ray
alone we conclude that this disease should
initially be treated with chemotherapy alone
to select those in whom further chemotherapy
is worthwhile. Also the role of radiotherapy
in these patients needs further study.
IMPAIRED WATER EXCRETION IN
OAT-CELL LUNG CANCER. E. D.
GIBY, P. K. BONDY and M. FORSLING,
Biology of Human Cancer Unit, Ludwig
Institute of Cancer Research, Royal Marsden
Hospital, London and Department of Physio-
logy, Middlesex Hospital Medical School,
London.
Water load tests and plasma arginine
vasopressin (AVP) assays were performed on
49 patients with untreated oat-cell carcinoma
of the lung. Only 15 patients displayed a
normal diuretic response with normal sup-
pression of plasma AVP. The syndrome of
inappropriate antidiuretic hormone secretion
was common, and usually asymptomatic. Its
presence in 17 patients (35%) was confirmed
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by observing elevated plasma AVP with
hypotonic plasma and concentrated urine.
The syndrome resolved after successful anti-
tumour chemotherapy but persisted in
patients who showed no tumour regression.
In the remaining 17 patients lesser degrees of
impaired water excretion occurred, with
variable AVP levels, possibly resulting from
stress of the illness. Plasma AVP levels do
not provide a reliable tumour marker in this
disease, but the syndrome of inappropriate
secretion is worth seeking, sinceit is common,
may be a guide to success of treatment and
may require treatment per se.
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